glp-1 agonists mechanism of action GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes Recent updates on GLP-1 agonists:

In 2017, GIP(3-30)NH 2 was confirmed to be highly selective for the human GIP receptor without any agonistic properties

Cognitive behavioral therapy (CBT) and interpersonal psychotherapy (IPT) remain first-line evidence-based treatments for BED, with robust data supporting their efficacy

Additionally, optimizing access and equity in pharmacotherapy, as well as integrating these treatments into comprehensive care models, are critical areas for future investigation

[DOI] [PubMed] [Google Scholar] 44.Sanyal A.J., Kaplan L.M., Frias J.P., Brouwers B., Wu Q., Thomas M.K., Harris C., Schloot N.C., Du Y., Mather K.J., et al

This context should be interpreted with a qualified healthcare provider as part of a comprehensive evaluation that includes medical history, biomarkers, and clinical goals

They arent backed up by solid science and their impact on GLP-1 in humans is still unknown.